Back to Search
Start Over
Inhibition of TGF-β Signaling Attenuates Disuse-induced Trabecular Bone Loss After Spinal Cord Injury in Male Mice.
- Source :
-
Endocrinology [Endocrinology] 2022 Jan 01; Vol. 163 (1). - Publication Year :
- 2022
-
Abstract
- Bone loss is one of the most common complications of immobilization after spinal cord injury (SCI). Whether transforming growth factor (TGF)-β signaling plays a role in SCI-induced disuse bone loss has not been determined. Thus, 16-week-old male mice underwent sham or spinal cord contusion injury to cause complete hindlimb paralysis. Five days later, 10 mg/kg/day control (IgG) or anti-TGF-β1,2,3 neutralizing antibody (1D11) was administered twice weekly for 4 weeks. Femurs were examined by micro-computed tomography (micro-CT) scanning and histology. Bone marrow (BM) supernatants were analyzed by enzyme-linked immunosorbent assay for levels of procollagen type 1 intact N-terminal propeptide (P1NP), tartrate-resistant acid phosphatase (TRAcP-5b), receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin (OPG), and prostaglandin E2 (PGE2). Distal femoral micro-CT analysis showed that SCI-1D11 mice had significantly (P < .05) attenuated loss of trabecular fractional bone volume (123% SCI-1D11 vs 69% SCI-IgG), thickness (98% vs 81%), and connectivity (112% vs 69%) and improved the structure model index (2.1 vs 2.7). Histomorphometry analysis revealed that osteoclast numbers were lower in the SCI-IgG mice than in sham-IgG control. Biochemically, SCI-IgG mice had higher levels of P1NP and PGE2 but similar TRAcP-5b and RANKL/OPG ratio to the sham-IgG group. The SCI-1D11 group exhibited higher levels of P1NP but similar TRAcP-5b, RANKL/OPG ratio, and PGE2 to the sham-1D11 group. Furthermore, 1D11 treatment prevented SCI-induced hyperphosphorylation of tau protein in osteocytes, an event that destabilizes the cytoskeleton. Together, inhibition of TGF-β signaling after SCI protects trabecular bone integrity, likely by balancing bone remodeling, inhibiting PGE2 elevation, and preserving the osteocyte cytoskeleton.<br /> (Published by Oxford University Press on behalf of the Endocrine Society 2021.)
- Subjects :
- Animals
Antibodies, Neutralizing chemistry
Bone Diseases, Metabolic metabolism
Bone Marrow metabolism
Bone Remodeling
Bone Resorption metabolism
Cytoskeleton metabolism
Dinoprostone metabolism
Disease Models, Animal
Homeostasis
Male
Mice
Mice, Inbred C57BL
Osteocytes metabolism
Osteoporosis
Osteoprotegerin metabolism
Peptides chemistry
Phosphorylation
RANK Ligand metabolism
Signal Transduction
Smad2 Protein metabolism
Spinal Cord Injuries physiopathology
X-Ray Microtomography
Bone and Bones metabolism
Cancellous Bone metabolism
Transforming Growth Factor beta antagonists & inhibitors
Transforming Growth Factor beta metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1945-7170
- Volume :
- 163
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 34791098
- Full Text :
- https://doi.org/10.1210/endocr/bqab230